肿瘤标志物CA153、CA125、CEA和SF联合检测对乳腺癌的诊断价值

目的探讨肿瘤标志物CA153、CA125、CEA和SF联合检测在乳腺癌中的临床应用价值。方法利用化学发光免疫方法检测60例乳腺良性疾病（乳腺良性疾病组）和4JD例健康体检者（对照组）以及60例乳腺癌患（乳腺癌组）治疗前后血清CA15．3、CA125,CEA和SF的水平，并进行分析。结果乳腺癌组治疗前CA153、CA125、CEA、SF水平（52．8±21．3）u／ml、（44．2±20.1）ng／ml、（8．9±5．2）ng／ml、（350．5±113．8）w／ml]均显著高于乳腺良性疾病组（17．3±8．8）u／ml、（15．6±8．5）u／ml、（2．0±0．8）u／ml、（1220．7±46．91）ng／ml]（t=2．671，t=2．684，t=2．898，t=2．844，P均〈0．01）；乳腺癌组患者血清CA153、CA125、CEA和SF治疗前的水平（同上）明显高于治疗后（25．5±3．7）u／ml、（15．0±8．4）u／ml、（4.6±3．3）ng／m1、（98．5±58．6）ng/ml]（t=2．210，t=2．165，t=2．224，t=2．234，P均〈0．05）；乳腺良性疾病组与正常对照组差异无统计学意义（t=1．644，t=1．757，t=1．67，t=1．741，P均〉0．05）；乳腺癌组CA153＋CA125＋CEA＋SF四项联检阳性率53．3％低于CA153（56．7％）、CA125（58．3％）、CEA（63．3％）、SF（68．3％）（x^2=2．52，x^2=2．652，P〉0．05；x^2=3．85，x^2=3.90，x^2=3．98，P〈0．05）。结论血清CA15—3、CA125、CEA、SF联合检测可提高乳腺癌的阳性检出率，对乳腺癌的早期诊断、疗效监测以及预后判断均有重要意义。

Clinical Significance of the detection of CA153,CA125,CEA and SF Serum Test in Breast Cancer

Objective To study the clinical significance of sernm CA153,CA125 and CEA test in breast cancer.Methods The levels of CA153,CA125,carcinoembryonic antigen(CEA)and ferritin were measured in 60 patients with breast cancer(breast cancer group),36 patients with benign breast diseases(benign breast diseases group)and 40 healthy people(control group)by chemiluminometry.The four indices were compared and analyzed for their complementary diagnostic value to breast cancer.Results The levels of CA153,CA125,CEA,SF(52.8±21.3)u/ml,(44.2±20.1)ng/ml,(8.9±5.2)ng/ml,(350.5±113.8)ng/ml]in breast cancer group were significantly higher than that of benign breast disease group(17.3±8.8)u/ml,(15.6±8.5)u/ml,(2.0±0.8)u/ml,(1220.7±46.91)ng/ml](t=2.671,t=2.684,t=2.898,t=2.844,P＜0.01);The levels of CA153,CA125,CEA and SF pretreatment in breast cancer group were significantly higher than that after treatment(25.5±3.7)u/ml,(15.0±8.4)u/ml,(4.6±3.3)ng/ml,(98.5±58.6)ng/ml](t=2.210,t=2.165,t=2.224,t=2.234,P＜0.05);The positive rate of 53.3%in breast cancer group for CA153+CA125+CEA+SF were lower than that CA153(56.7%),CA125(58.3%),CEA(63.3%),SF(68.3%)(χ~2=2.52,χ~2=2.652,P＞0.05;χ~2=3.85,χ~2=3.90,χ~2=3.98,P＜0.05);joint determination of CA153+CEA+SF experimental efficient 89.0%higher than the other four groups of the joint determination,but had no signiflcanle(χ~2=2.78,χ~2=3.10,χ~2=2.99,χ~2=3.01,P＞0.05).Conclusion The positive rate may be increased by combining test of serum CA153,CA125,CEA and ferritin in breast cancer.Thus the combined test might be of high value for the early diagnosis,improving the therapeutic effect and prognosis of breast cancer.